Steve Chaplin, Surya Rajeev and John Wilding December 9, 2015 26.11 5 June 2015
Empagliflozin (Jardiance) is the third SGLT2 inhibitor available for the treatment of type 2 diabetes. Here we present the clinical data relating to its efficacy and adverse events.
Jardiance the latest SGLT2 for the treatment of type 2 diabetes
PrescriberMailing list request
Registration is for health professionals only and gives free access to our content.
Job Title (required)
---CCGCommunity NurseCommunity PharmacistGPGP prescribing leadNon-medical PrescriberPractice NursePractice PharmacistOther (specify below)
Other Job Title
Clinical specialism/interest (required)
Would you like to receive the e-newsletter for this title?
Would you like to receive print copies for this title?
Yes (please complete address details below)No
Address Line 1
Address Line 2